Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Biocept, Inc. (BIOC) Business Update Conference Call (Transcript) | seekingalpha.com • |
Biocept to Hold Business Update Conference Call on August 30, 2023 | businesswire.com • |
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole | investorplace.com • |
Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference | proactiveinvestors.com • |
Biocept appoints Antonino Morales as president and chief executive officer | proactiveinvestors.com • |
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023 | businesswire.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2023-11-20 | 2023-09 | 0 | N/A | N/A | N/A |
2023-05-10 | 2023-03 | 0 | N/A | N/A | N/A |
2023-04-17 | 2022-12 | 0 | N/A | N/A | N/A |
2022-11-21 | 2022-09 | -4.8 | N/A | N/A | N/A |
2022-11-10 | 2022-06 | 0 | N/A | N/A | N/A |
2022-05-23 | 2022-03 | -7.21 | N/A | N/A | N/A |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-12-08 | HALE DAVID F | Director | 0.00 | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Anson Funds Management LP | 44.86K | 54.28K | 1.71% |
2023-06-29 | Boothbay Fund Management, LLC | 23.53K | 28.47K | 0.90% |
2023-06-29 | Tower Research Capital LLC (TRC) | 5.39K | 6.52K | 0.21% |
2023-06-29 | Blackrock Inc. | 5.26K | 6.37K | 0.20% |
2023-06-29 | Acadian Asset Management. LLC | 247.00 | 298.00 | 0.01% |
2023-06-29 | Group One Trading, L.P. | 270.00 | 326.00 | 0.01% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 4.43K | 5.37K | 0.17% |
2023-05-30 | Fidelity Extended Market Index Fund | 2.95K | 6.38K | 0.11% |
2023-05-30 | Fidelity Series Total Market Index Fund | 644.00 | 1.39K | 0.02% |
2023-05-30 | Fidelity Total Market Index Fund | 488.00 | 1.05K | 0.02% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 189.00 | 408.00 | 0.01% |
Split | Date |
---|---|
1 : 30 | 2023-05-17 |
1 : 10 | 2020-09-08 |
1 : 30 | 2018-07-10 |
1 : 3 | 2016-09-29 |
-
Any expert whats going on explain
-
Today power hour is a fire hour stight to tomorrow pumps get help .45 then market opens .60 moving moving
-
I’m hearing some sound like ohhhhhhhh yeeeeeessssssss yeaaaaahhhhhhhh do it do it they goodens can I hearing ohhhhh yeahhhhh its moving
-
40 mil volume and no movement After patent release?
-
This holly shit fucker only pump last 5 mintus closing history ask other bag holder
-
Hey mother fucker nothing news they ibio goes green today what hell you goona red
-
Same my opens at 19000 shares .47
-
Why it’s getting down
-
Give me 1$
-
.40$ coming
-
Give me .40
-
Big buy no movement
-
Give me .38
-
I want to see .40
-
Would have made a fortune just shorting this thing. Up 2 penny’s one day down 4 the next
-
Run to $2
-
Ruined my year
-
no reason to fall... should be at least $0.5
-
no reason to fall
-
Should be criminal
-
Biocept, Inc. (BIOC) Business Update Conference Call (Transcript)
seekingalpha.com • -
Biocept to Hold Business Update Conference Call on August 30, 2023
businesswire.com • -
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
investorplace.com • -
Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference
proactiveinvestors.com • -
Biocept appoints Antonino Morales as president and chief executive officer
proactiveinvestors.com • -
Why Is Biocept (BIOC) Stock Down 42% Today?
investorplace.com • -
Biocept shares to commence trading on split-adjusted basis
proactiveinvestors.com • -
Biocept, Inc. (BIOC) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
Biocept reports 176% year-over-year jump in orders for CNSide assay
proactiveinvestors.com • -
Biocept adds CPA Quyen Dao-Haddock to board, bringing extensive financial acumen to audit committee
proactiveinvestors.com • -
Biocept to use CNSide assay in study looking at biomarkers in patients with metastatic breast cancer
proactiveinvestors.com • -
Biocept to Hold Business Strategy Conference Call Today
businesswire.com • -
Biocept sees 1Q net revenue rise 12% driven by its coronavirus testing services
proactiveinvestors.com • -
Biocept, Inc. says coronavirus testing drove strong rise in full-year 2021 revenue
proactiveinvestors.com • -
Biocept reports unaudited net revenue of $61.2 million for 2021
proactiveinvestors.com • -
Biocept appoints Samuel Riccitelli as its interim CEO and Antonino Morales as interim CFO
proactiveinvestors.com • -
Biocept appoints Darrell Taylor as its new chief compliance officer
proactiveinvestors.com • -
Biocept says demand for its COVID-19 RT-PCR testing increases in 2022 amid Omicron variant surge
proactiveinvestors.com • -
Biocept launches single test for COVID-19 and Influenza as cases rise during flu season
proactiveinvestors.com • -
Biocept sees profitability in third quarter thanks to increased RT-PCR COVID-19 testing
proactiveinvestors.com • -
7 of the Best Penny Stocks to Buy Coming Into Year-End
investorplace.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept reports profitability for the first half on back of increased COVID-19 testing
proactiveinvestors.com • -
Biocept appoints David Karlander as senior vice president of Commercial Operations
proactiveinvestors.com • -
Biocept bolsters board of directors and names Samuel D Riccitelli as new chairman
proactiveinvestors.com • -
Biocept joins the Russell Microcap Index
proactiveinvestors.com • -
Biocept Joins the Russell Microcap® Index
businesswire.com • -
Wall Street takes a turn for the worse as investors eye Fed
proactiveinvestors.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept makes coronavirus testing available for California's 116 community colleges
proactiveinvestors.com • -
Biocept launches its CNSide cerebrospinal fluid assay for early detection of metastatic brain cancer
proactiveinvestors.com • -
Biocept says its lab received to-date more than 350,000 coronavirus testing samples for processing
proactiveinvestors.com • -
Biocept: Record Revenues And Profits Support Speculative Buy
seekingalpha.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept: Q4 Earnings Insights
benzinga.com • -
Biocept to Participate in Three Virtual Investment Conferences in March
businesswire.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept to Present at H.C. Wainwright Virtual BioConnect Conference
prnewswire.com • -
Analyzing Teleflex (NYSE:TFX) & Viatar CTC Solutions (NYSE:VRTT)
thelincolnianonline.com •